← All organizations
European Organisation for Research and Treatment of Cancer
Academic/HospitalWebsite ↗
Also known as: EORTC study coordinator | EORTC Study Coordinator | European Organisation for Research and Treatment Center (EORTC) | European Organisation for Research and Treatment of Cancer - EORTC
Highest phase reached
Phase 4
First clinical trial
Nov 1, 1986Last known activity
Apr 30, 2026
Timeline
1960s
- Jan 1, 1962
European Organisation for Research and Treatment of Cancer— Founded
Drugs by trial phase (227 distinct, 340 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 3 (131 own, 0 via acquisition)
Phase 2 (78 own, 0 via acquisition)
Phase 1 (12 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Studied for
- Activated Protein C Resistance
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Adenomyoepithelioma
- Anemia
- Anus Neoplasms
- Aspergillosis
- Astrocytoma
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoid Heart Disease
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Adenoid Cystic
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Central Nervous System Neoplasms
- Cholangiocarcinoma
- Choriocarcinoma
- Cognition Disorders
- Colonic Neoplasms
- Colorectal Neoplasms
- Dermatofibrosarcoma
- Drug-Related Side Effects and Adverse Reactions
- Endodermal Sinus Tumor
- Endometrial Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Fever
- Gallbladder Neoplasms
- Gastrointestinal Stromal Tumors
- Germinoma
- Giant Cell Tumor of Bone
- Giant Cell Tumors
- Glioblastoma
- Glioma
- Gliosarcoma
- Granuloma, Plasma Cell
- Head and Neck Neoplasms
- Heart Diseases
- Hodgkin Disease
- Hot Flashes
- Infections
- Inflammatory Breast Neoplasms
- Intestinal Neoplasms
- Kidney Neoplasms
- Laryngeal Diseases
- Leiomyosarcoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Promyelocytic, Acute
- Liposarcoma
- Liver Neoplasms
- Lung Neoplasms
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Malignant Carcinoid Syndrome
- Mediastinal Neoplasms
- Medulloblastoma
- Melanoma
- Meningioma
- Mesothelioma
- Multiple Myeloma
- Mycoses
- Mycosis Fungoides
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Nasopharyngeal Neoplasms
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neoplasms, Squamous Cell
- Neoplastic Cells, Circulating
- Nervous System Neoplasms
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Neuroendocrine Tumors
- Neutropenia
- Oligodendroglioma
- Osteosarcoma
- Ovarian Neoplasms
- Pancreatic Neoplasms
Recent trials (50)
- NCT07234877Lead sponsorPhase 2Apr 30, 2026
- NCT06978062Lead sponsorPhase 1Feb 20, 2026
- NCT06809322Lead sponsorPhase 3Dec 5, 2025
- NCT06783348Lead sponsorPhase 2Oct 30, 2025
- NCT06407401Lead sponsorPhase 3Dec 31, 2024
- NCT06326190Lead sponsorPhase 2Nov 6, 2024
- NCT06326190OfficialPhase 2Nov 6, 2024
- NCT06219317Lead sponsorPhase 2Oct 31, 2024
- NCT06246149Lead sponsorPhase 3Oct 31, 2024
- NCT05904119Overall official - principal investigatorPhase 3Mar 31, 2024
- NCT05904119Lead sponsorPhase 3Mar 31, 2024
- NCT05815927Lead sponsorPhase 3Jan 1, 2024
- NCT05724602Lead sponsorPhase 2Nov 15, 2023
- NCT05512364Lead sponsorPhase 3May 1, 2023
- NCT05209529Lead sponsorPhase 2Sep 1, 2022
Details
- Founded
- Brussels, BE Jan 1, 1962
- Last known activity
- Apr 30, 2026